Trials / Unknown
UnknownNCT04365439
Convalescent Plasma for COVID-19
Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Enos Bernasconi · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: * the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment; * the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment; * the impact of plasma transfusion on the reduction of viral load and inflammation * safety and tolerability * clinical efficacy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Blood plasma | Convalescent plasma after COVID-19 |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2020-12-20
- Completion
- 2021-06-30
- First posted
- 2020-04-28
- Last updated
- 2021-03-29
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04365439. Inclusion in this directory is not an endorsement.